Performance and Predictors of Migration of Partially and Fully Covered Esophageal Self-Expanding Metal Stents for Malignant Dysphagia.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
12 2021
Historique:
received: 22 05 2020
revised: 24 08 2020
accepted: 02 09 2020
pubmed: 9 9 2020
medline: 27 1 2022
entrez: 8 9 2020
Statut: ppublish

Résumé

Self-expanding metal stents (SEMS) are routinely used to palliate malignant dysphagia. However esophageal SEMS can migrate or obstruct due to epithelial hyperplasia. The aim of this study was to evaluate the rates and factors predicting migration and obstruction, and the nutritional outcomes in partially covered (pc) vs. fully covered (fc) SEMS vs. fcSEMS with antimigration fins (AF) placed for malignant dysphagia. A retrospective review of consecutive patients undergoing SEMS placement for malignant dysphagia at three academic medical centers. Among 357 patients, there were 55 (15.4%) stent migrations, 45 (12.6%) obstructions from epithelial hyperplasia, and 20 (5.6%) food impactions. Median overall survival was 79 days (IQR 41,199). The percent weight change/change in albumin at 30 and 60 days after SEMS placement were -2.24%/-0.544 g/dL and -2.98%/-0.55 g/dL, respectively. Stent migration occurred significantly more often with fcSEMS than pcSEMS (25.3% vs 10.9%; P < .003), but there was no difference when either group was compared to fcSEMS-AF (19.3%). The overall rate of epithelial hyperplasia resulting in stent obstruction was low (12.6%) and not different between stent types. Factors associated with increased risk of SEMS migration on multivariable logistic regression included stricture traversability with a diagnostic endoscope (OR, 2.37; 95% CI, 1.29-4.35) and use of fcSEMS (OR, 2.56; 1.31-5.00) or fcSEMS-AF (OR, 2.30, 1.03-5.14). Traversability of a malignant esophageal stenosis predicts SEMS migration. In these patients with a limited overall survival, pcSEMS are associated with lower rates of stent migration and similar rates of obstruction compared to fcSEMS.

Sections du résumé

BACKGROUND & AIMS
Self-expanding metal stents (SEMS) are routinely used to palliate malignant dysphagia. However esophageal SEMS can migrate or obstruct due to epithelial hyperplasia. The aim of this study was to evaluate the rates and factors predicting migration and obstruction, and the nutritional outcomes in partially covered (pc) vs. fully covered (fc) SEMS vs. fcSEMS with antimigration fins (AF) placed for malignant dysphagia.
METHODS
A retrospective review of consecutive patients undergoing SEMS placement for malignant dysphagia at three academic medical centers.
RESULTS
Among 357 patients, there were 55 (15.4%) stent migrations, 45 (12.6%) obstructions from epithelial hyperplasia, and 20 (5.6%) food impactions. Median overall survival was 79 days (IQR 41,199). The percent weight change/change in albumin at 30 and 60 days after SEMS placement were -2.24%/-0.544 g/dL and -2.98%/-0.55 g/dL, respectively. Stent migration occurred significantly more often with fcSEMS than pcSEMS (25.3% vs 10.9%; P < .003), but there was no difference when either group was compared to fcSEMS-AF (19.3%). The overall rate of epithelial hyperplasia resulting in stent obstruction was low (12.6%) and not different between stent types. Factors associated with increased risk of SEMS migration on multivariable logistic regression included stricture traversability with a diagnostic endoscope (OR, 2.37; 95% CI, 1.29-4.35) and use of fcSEMS (OR, 2.56; 1.31-5.00) or fcSEMS-AF (OR, 2.30, 1.03-5.14).
CONCLUSIONS
Traversability of a malignant esophageal stenosis predicts SEMS migration. In these patients with a limited overall survival, pcSEMS are associated with lower rates of stent migration and similar rates of obstruction compared to fcSEMS.

Identifiants

pubmed: 32898705
pii: S1542-3565(20)31238-6
doi: 10.1016/j.cgh.2020.09.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2656-2663.e2

Informations de copyright

Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Koushik K Das (KK)

Division of Gastroenterology, Washington University, St. Louis, Missouri. Electronic address: k.das@wustl.edu.

Stephen Hasak (S)

Division of Gastroenterology, Washington University, St. Louis, Missouri.

Sherif Elhanafi (S)

Division of Gastroenterology, Texas Tech University Health Sciences Center, El Paso, Texas.

Kavel H Visrodia (KH)

Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.

Gregory G Ginsberg (GG)

Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Nuzhat A Ahmad (NA)

Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Thomas Hollander (T)

Division of Gastroenterology, Washington University, St. Louis, Missouri.

Gabriel Lang (G)

Division of Gastroenterology, Washington University, St. Louis, Missouri.

Vladimir M Kushnir (VM)

Division of Gastroenterology, Washington University, St. Louis, Missouri.

Daniel K Mullady (DK)

Division of Gastroenterology, Washington University, St. Louis, Missouri.

Barham K Abu Dayyeh (BK)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Navtej S Buttar (NS)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Louis Michel Wong Kee Song (LM)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Michael L Kochman (ML)

Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Vinay Chandrasekhara (V)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH